SciGen signs US$145m hep B distribution deal
Monday, 10 October, 2005
Singapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac.
"This is a very significant commercial deal for SciGen," said SciGen CEO Saul Mashaal in a statement. "The sales targets to which HID has agreed are substantive, yet the agreement allows SciGen considerable control over the future of Sci-B-Vac sales and marketing in China."
Under the agreement HID is required to order and pay for a minimum annual quantity of six million doses of Sci-B-Vac, either as dispensed doses or bulk antigen, for a period seven years. Over this period revenues for doses are expected at US$210 million or US$145 if HID chooses to purchase bulk antigen.
Sci-B-Vac is a third generation recombinant hepatitis B vaccine produced in Chinese hampster ovary (CHO) cells (mammalian cell). It contains a mixture of three regions of the hepatitis B virus surface proteins that according to SciGen stimulates a faster immune response than other hepatitis B vaccine presently available.
HID has been appointed as the non-exclusive distributor of Sci-B-Vac to customers in China and SciGen has retained the right to sell the product directly in China or to appoint other distributors.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
